Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.
Bluestar Genomics, a US-based cancer diagnostics technology developer spun out of Stanford University, raised $70m in a series C round led by Mattias Westman, founding partner of asset management firm Prosperity Capital Management.
Medical diagnostics group Pathology Asia Holdings also participated in the round, as did an undisclosed venture capital fund and an unnamed asset manager also took part.
Bluestar is exploring cancer screening products focusing on the genetic material of cells, otherwise known as the epigenome. It is working on a non-invasive test for pancreatic cancer based on research in Steven Quake’s laboratory.
The company has not revealed any earlier funding. It announced the series C round together with its appointment of Felix Feng, professor of radiation oncology, urology and medicine at University of California, San Francisco, and Craig Venter, CEO of J Craig Venter Institute, to its scientific advisory board.
Samuel Levy, chief executive…
